Treatment options for necrobiosis lipoidica: a systematic review
International Journal of Dermatology · 2023-12 · 62 (12) · 1529-1537
DOI: 10.1111/ijd.16856 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift International Journal of Dermatology, online erschienen am 29.09.2023. Verfasst von Aman Nihal und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. Hauptthemen laut MEDLINE: Necrobiosis Lipoidica, Janus Kinase Inhibitors. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Necrobiosis lipoidica (NL) is a rare, idiopathic, and recalcitrant disease of collagen degeneration for which treatment options have been poorly studied. Due to its recurring nature, risk for ulceration, and high morbidity, there is a need to understand existing treatment modalities to better inform clinical care.
Objective
This review aims to describe the therapeutic modalities reported in the literature for the treatment of NL.
Methods
A literature search of treatments was performed by searching for publications between January 2016 and May 2022 on PubMed and Scopus. Given the limited high‐quality evidence, case reports and series were included. Only publications presenting information on both attempted treatments and outcomes were included.
Results
A total of 60 novel articles were identified (54 case reports, two case series, and four retrospective cohort studies). These studies cumulatively reported on 274 patients and covered treatments including phototherapy, topical corticosteroids, topical calcineurin inhibitors, biologics, immunosuppressants, JAK inhibitors, combination therapies, and several others. The greatest amount of evidence was found for photodynamic therapy (improvement in 72 of 80 patients), UVA‐based phototherapy (12 of 33), topical corticosteroids (21 of 46), compression therapy (15 of 20), and topical calcineurin inhibitors (11 of 17). Several newer treatments were also described, including ustekinumab and JAK inhibitors.
Conclusions
This systematic review provides a comprehensive summary of recently published treatments for NL. As the existing data comes predominantly from case reports and series, statistical conclusions are not assessed. A greater number of randomized controlled trials with standardized endpoints are necessary to compare treatment efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
- Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, NY, USA.
- Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA.
- Department of Dermatology, Yale University, New Haven, CT, USA.
- Department of Dermatology, Mayo Clinic, Scottsdale, AZ, USA.
Zitieren
APA
Nihal, A., Caplan, A. S., Rosenbach, M., Damsky, W., Mangold, A. R., & Shields, B. E. (2023). Treatment options for necrobiosis lipoidica: a systematic review. International Journal of Dermatology, 62(12), 1529-1537. https://doi.org/10.1111/ijd.16856
Vancouver
Nihal A, Caplan AS, Rosenbach M, Damsky W, Mangold AR, Shields BE. Treatment options for necrobiosis lipoidica: a systematic review. International Journal of Dermatology. 2023;62(12):1529-1537. doi:10.1111/ijd.16856
BibTeX
@article{Nihal2023,
author = {Nihal, Aman and Caplan, Avrom S and Rosenbach, Misha and Damsky, William and Mangold, Aaron R and Shields, Bridget E},
title = {Treatment options for necrobiosis lipoidica: a systematic review},
journal = {International Journal of Dermatology},
year = {2023},
volume = {62},
number = {12},
pages = {1529--1537},
doi = {10.1111/ijd.16856}
}
EUVIMED